|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
82,270,000 |
Market
Cap: |
352.94(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.29 - $35.72 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.1 |
Insider 6 Months : 8.1 |
Insider 3/6 Months : 16.7 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Revance Therapeutics is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. Co.'s segments are: Product, which refers to the business that includes the research, development and commercialization of its product candidates and the RHA® Collection of dermal fillers; and Service, which refers to the business that includes the development and commercialization of the OPUL Relational Commerce Platform and HintMD platform.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
30,000 |
30,000 |
30,000 |
30,000 |
Total Buy Value |
$209,400 |
$209,400 |
$209,400 |
$209,400 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
29,089 |
29,089 |
291,945 |
446,160 |
Total Sell Value |
$143,717 |
$143,717 |
$7,898,916 |
$12,719,522 |
Total People Sold |
4 |
4 |
5 |
5 |
Total Sell Transactions |
4 |
4 |
17 |
27 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nolet Chris |
Director |
|
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
43,606 |
|
- |
|
Coric Vlad |
Director |
|
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
20,784 |
|
- |
|
Gangolli Julian S |
Director |
|
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
45,106 |
|
- |
|
Ware Olivia C |
Director |
|
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
31,675 |
|
- |
|
Beraud Jill |
Director |
|
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
43,606 |
|
- |
|
Russell Angus C. |
Director |
|
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
51,506 |
|
- |
|
Kolaja Carey Oconnor |
Director |
|
2024-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
31,561 |
|
- |
|
Jordan Erica |
Chief Commercial Officer |
|
2024-04-16 |
4 |
S |
$3.80 |
$9,096 |
D/D |
(2,392) |
114,864 |
|
-13% |
|
Schilke Tobin |
CFO |
|
2024-03-18 |
4 |
S |
$5.04 |
$47,204 |
D/D |
(9,361) |
192,666 |
|
13% |
|
Sjuts Dustin S |
President |
|
2024-03-18 |
4 |
S |
$5.04 |
$46,446 |
D/D |
(9,211) |
167,550 |
|
13% |
|
Moxie Dwight |
CLO & GC |
|
2024-03-18 |
4 |
S |
$5.04 |
$40,971 |
D/D |
(8,125) |
137,815 |
|
13% |
|
Schilke Tobin |
CFO |
|
2024-03-15 |
4 |
D |
$5.31 |
$20,276 |
D/D |
(3,822) |
202,027 |
|
- |
|
Sjuts Dustin S |
President |
|
2024-03-15 |
4 |
D |
$5.31 |
$15,740 |
D/D |
(2,967) |
176,761 |
|
- |
|
Moxie Dwight |
CLO & GC |
|
2024-03-15 |
4 |
D |
$5.31 |
$17,342 |
D/D |
(3,269) |
145,940 |
|
- |
|
Foley Mark J |
CEO |
|
2024-03-15 |
4 |
D |
$5.31 |
$108,928 |
D/D |
(20,533) |
994,935 |
|
- |
|
Foley Mark J |
CEO |
|
2024-03-06 |
4 |
B |
$6.98 |
$209,400 |
D/D |
30,000 |
1,015,468 |
2.81 |
-32% |
|
Foley Mark J |
CEO |
|
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
70,750 |
985,468 |
|
- |
|
Sjuts Dustin S |
President |
|
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
22,110 |
179,728 |
|
- |
|
Moxie Dwight |
CLO & GC |
|
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
15,143 |
149,209 |
|
- |
|
Schilke Tobin |
CFO |
|
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
17,447 |
205,849 |
|
- |
|
Hollander David |
CMO & Global Therapeutics Lead |
|
2024-02-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
108,853 |
|
-25% |
|
Jordan Erica |
Chief Commercial OfficerOffice |
|
2024-02-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
117,256 |
|
-25% |
|
Schilke Tobin |
CFO |
|
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
96,667 |
188,402 |
|
- |
|
Moxie Dwight |
SVP, GC & Secretary |
|
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
134,066 |
|
- |
|
Foley Mark J |
CEO |
|
2023-12-31 |
4 |
A |
$7.47 |
$1,972 |
D/D |
264 |
914,718 |
|
- |
|
422 Records found
|
|
Page 1 of 17 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|